Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
Women with HIV disease: clinical progression and survival in a cohort followed at a university medical center.
Int Conf AIDS. 1992 Jul 19-24;8(1):Mo11 (abstract no. MoC 0034). Unique Identifier : AIDSLINE ICA8/92399992 Benson C; Sha B; Urbanski P; Pottage J; Kessler H; Rush Medical College, Chicago, IL.
Abstract:
OBJECTIVE: To evaluate the clinical progression and overall survival following the diagnosis of HIV infection in a cohort of women followed at a university medical center. DESIGN: Single site, longitudinal, observational study. METHODS: Women evaluated in the HIV Treatment Program at Rush were included if they were seen on greater than or equal to 2 visits and followed for greater than or equal to 3 months. Data were collected at baseline and 1, 2 or 6 month intervals, respectively, for patients with AIDS, symptomatic or asymptomatic disease at entry. RESULTS: 77 women were evaluated from 10/86 to 1/92; 63 met the inclusion criteria. The median age was 33 yrs. Median duration of follow-up was 12 months (range 3-57). Overall, 33/63 (52%) were white, 23 (37%) were black, and 7 (11%) were hispanic; 45% were uninsured. Risk factors included high risk sex contact (60%), IDU (22%), blood transfusion (16%) and unknown (6%). At entry, 12 (19%) had AIDS (median CD4 17/mm3) of whom 8 (75%) subsequently died; 29 (46%) had symptomatic HIV disease (median CD4 207/mm3) of whom 6 (21%) progressed to AIDS and 3 (10%) died; and 22 (35%) were asymptomatic (median CD4 528/mm3) of whom 6 (27%) progressed to AIDS or symptomatic disease and 1 died. Overall, 10/20 patients (50%) who had or developed AIDS died. Median time (Kaplan-Meier) from initial HIV diagnosis to AIDS was 68 months. Median survival (Kaplan-Meier) from initial HIV diagnosis was greater than 44 months. Median survival following an AIDS diagnosis was 27 months. Among those with AIDS, Candida esophagitis (65%) was the most frequent OI, followed by PCP (40%), and MAC disease (30%). Gynecologic abnormalities occurred in 21 (33%); these included recurrent Candida vaginitis (32%), abnormal PAP smears/CIN (10%), and PID (8%). Overall, 49 (78%) received antiretroviral therapy; 52% participated in clinical trials (16 white, 12 black, 5 hispanic; 45% uninsured). CONCLUSIONS: With the exception of gynecologic abnormalities and the more frequent occurrence of Candida esophagitis, HIV disease progression, development of other OIs, and survival among this cohort of women, with access to medical care and clinical trials, is similar to that of previously described cohorts of gay men.
Keywords: Adult Chicago/EPIDEMIOLOGY Cohort Studies Ethnic Groups Female Follow-Up Studies Human HIV Infections/COMPLICATIONS/*MORTALITY/TRANSMISSION Life Tables Medically Uninsured Opportunistic Infections/COMPLICATIONS/EPIDEMIOLOGY Risk Factors Substance Abuse, Intravenous/COMPLICATIONS/EPIDEMIOLOGY Survival Analysis Survival Rate ABSTRACT 921230
M92C5355
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
